Navigation Links
AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
Date:11/24/2009

    Primary efficacy endpoint has been met for patients with advanced-stage
    or recurrent endometrial cancer

QUEBEC CITY, Nov. 24 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with advanced or recurrent endometrial cancer. In a personalized health care approach, the study selected patients with tumors expressing luteinizing hormone-releasing hormone (LHRH) receptors, the key element in the targeting mechanism of AEZS-108. Under the coordination of Prof. Gunter Emons, MD, Chairman of the Department of Obstetrics & Gynaecology at the University of Gottingen, Germany, this open-label, multi-center and multi-national Phase 2 study AGO-GYN 5, is being conducted by the German AGO Study Group (Arbeitsgemeinschaft Gynakologische Onkologie/Gynaecological Oncology Working Group; www.ago-ovar.de), in cooperation with clinical sites in Europe.

Preliminary Results

A preliminary evaluation has shown that the study AGO-GYN 5 met its predefined primary efficacy endpoint of 5 or more responder patients with endometrial cancer. The study is currently ongoing, and responders, as well as patients with stable disease after completion of treatment with AEZS-108, will be followed to assess the duration of progression-free survival and, ultimately, overall survival. Detailed analyses of the study results will be presented at forthcoming scientific conferences.

Juergen Engel, Ph.D., President and Chief Executive Officer at AEterna Zentaris stated, "We are pleased with the progress of this Ph
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... -- Pfenex Inc. (NYSE MKT: PFNX) a clinical-stage biotechnology company ... value and difficult to manufacture proteins, today announced the ... of its common stock at a price to the ... offered, 2,610,000 are being offered by Pfenex and the ... Pfenex will not receive any proceeds from the shares ...
(Date:4/24/2015)... 24, 2015 Seoul Semiconductor announced ... various applications in the lighting market. In ... of this technology in emerging markets such as ... wide range of applications such as streetlight and ... lighting. , First launched in 2005 the Acrich ...
(Date:4/23/2015)... , April 23, 2015 /CNW/ - A new and ... award from North America,s ... Comparison won Silver in the "Sustainability, service" category ... The Brandcheck "Competitor Comparison" is a service that ... American and Global peers. This benchmarking process shows ...
(Date:4/23/2015)... April 23, 2015 WuXi PharmaTech (Cayman) Inc. ... and technology platform company serving the pharmaceutical, biotechnology and ... and the United States ... for the first quarter of 2015 after the New ... (which will be Thursday morning, May 14, 2015 Shanghai ...
Breaking Biology Technology:Pfenex Inc. Announces Pricing Of Follow-on Offering 2Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3
... Renovis,Inc. (Nasdaq: RNVS ), a biopharmaceutical company ... medical needs in the areas of,neurological and inflammatory diseases, ... 30, 2007. Revenue for the third quarter and ... and $8.5 million, respectively, compared to $2.2,million and $8.3 ...
... Pathwork Diagnostics, a,genomics-based diagnostics company focused on oncology, ... has initiated an,investigational study of the Pathwork(TM) Tissue ... to help determine a tumor,s origin so that,tissue-specific ... of the first,institutions in the country to evaluate ...
... Airborne Biological Threats Receives Government ... ... ICx Technologies, a developer of,advanced technology solutions for homeland and ... ambient aerosol,sensors for detection of airborne biological threats. The AirSentinel,sensors, ...
Cached Biology Technology:Renovis Reports Third Quarter 2007 Financial Results 2Renovis Reports Third Quarter 2007 Financial Results 3Renovis Reports Third Quarter 2007 Financial Results 4Renovis Reports Third Quarter 2007 Financial Results 5Renovis Reports Third Quarter 2007 Financial Results 6Renovis Reports Third Quarter 2007 Financial Results 7Renovis Reports Third Quarter 2007 Financial Results 8Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics' Tissue of Origin Test Designed to Aid in Determination of a Tumor's Origin 2Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics' Tissue of Origin Test Designed to Aid in Determination of a Tumor's Origin 3Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics' Tissue of Origin Test Designed to Aid in Determination of a Tumor's Origin 4ICx Awarded Department of Defense Contract for AirSentinel Monitors 2
(Date:3/24/2015)... NexID Biometrics LLC, whose spoof-mitigation technology boosts protection ... beginning of shipments of version 2.0 of its industry ... in Potsdam, N.Y. , is making ... here today at the Walter E. Washington Convention Center. ... boosts the accuracy rate range to 96.5 to 99.5 ...
(Date:3/23/2015)... SoundView Technology Group issues a new research update following the ... wallet. SoundView was one of the selected user groups to provide ... in multiple scenarios and outlets. Soundview shares ... both debit and credit card payments.  Soundview ... meets their plans in 2015, it would push our IV ...
(Date:3/23/2015)... 2015  In the 2014 fiscal year, irs.gov recorded ... This figure accounts for a fraction of the estimated ... Report, exceeds $11 billion globally. The polygraph has traditionally ... has occurred. Investor Mark Saint Juste along ... Paolella partnered to administer the test in a ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... can serve as important sources of social and emotional support ... according to research published by the American Psychological Association. ... close to key people in their lives as to their ... the expense of relationships with other people, or that people ...
... technical, medical, and scholarly (STMS) business of global publisher ... increase in the number and proportion of its journal ... included in the Thomson ISI 2010 Journal Citation Reports ... from the 2009 JCR and includes 58 titles which ...
... vitamin D insufficiency and deficiency among patients with psoriatic ... observed in patients in southern or northern locations. The ... , a journal of the American College of Rheumatology ... vitamin D level. Psoriasis is a common ...
Cached Biology News:The truth about cats and dogs: Pets are good for mental health of 'everyday people' 2Wiley-Blackwell announces continued growth in impact factor journals 2Wiley-Blackwell announces continued growth in impact factor journals 3Wiley-Blackwell announces continued growth in impact factor journals 4Wiley-Blackwell announces continued growth in impact factor journals 5Vitamin D insufficiency prevalent among psoriatic arthritis suffers 2
...
... Cell Dissociation Buffers are membrane-filtered ... salts chelating agents and cell-conditioning agents ... balanced salt solution or Ca2+- ... dissociation of mammalian cells from support ...
... are membrane-filtered isotonic and enzyme-free aqueous ... cell-conditioning agents in either Ca2+- and ... Ca2+- and Mg2+-free phosphate-buffered saline ... from support substrates and each other ...
... Antibody Modification Services ,,GenScript offers ... labeling and antibody fragmentation. Labeling antibodies ... for visualization and quantitation of the ... is preferable to use only the ...
Biology Products: